Practice

Jeffery Casberg Previews His Presentations at AMCP 2022

March 27th 2022

By Skylar Jeremias

Jeffrey Casberg, vice president of pharmacy at IPD Analytics, previews his sessions about the new and emerging pharmaceutical products coming down the pipeline at the upcoming Academy of Managed Care Pharmacy (AMCP) annual meeting.

Kathy Oubre Shares Her Take on How the US Biosimilar Market Is Maturing

March 20th 2022

By Skylar Jeremias

Video

Kathy Oubre, MS, chief executive officer of Pontchartrain Cancer Center, explains the progress she has seen regarding biosimilar utilization and acceptance.

Trastuzumab-qyyp Maintains Stability and Potency Under Extended In-Use Conditions

March 15th 2022

By Deana Ferreri, PhD

Article

Pfizer’s trastuzumab biosimilar (trastuzumab-qyyp; Trazimera) was stable and efficacious under conditions of extended use in patients with breast cancer, investigators concluded.

Civica Initiates Project to Manufacture, Distribute Insulin Biosimilars for Uninsured Patients

March 7th 2022

By Skylar Jeremias

Article

Civica Rx will collaborate with companies to manufacture and distribute 3 insulin biosimilars and will offer them at an affordable price to uninsured and underinsured patients.

Kathy Oubre Explains How Biosimilar Savings Help Dispel Clinician Worries

March 6th 2022

By Skylar Jeremias

Video

Kathy Oubre, MS, chief operating officer of Pontchartrain Cancer Center, explains how biosimilars are helping to rid clinicians of their worries about the affordability of biologic drugs.

Switching to Samsung Bioepis’ Adalimumab Biosimilar Found to Be Safe in Patients With Crohn Disease

February 26th 2022

By Skylar Jeremias

Article

Switching patients with Crohn disease from reference adalimumab to SB5, a Samsung Bioepis biosimilar, did not lead to major changes in disease activity in a real-world analysis.

What Employers Can Do to Stand Up for Biosimilar Formulary Placement

February 24th 2022

By Skylar Jeremias

Article

A report from the National Alliance of Healthcare Purchaser Coalitions detailed the common concerns employers have regarding implementing biosimilars within their health care plans and outlined how they could take charge and make a difference.

CMS Seeks Answers for Slower-Than-Expected Biosimilar Adoption, Rawal Says

February 21st 2022

By Mary Caffrey

Article

Purva Rawal, PhD, senior advisor and chief strategy officer, Center for Medicare and Medicaid Innovation, spoke during the Association for Accessible Medicines' Access! annual meeting, which gathered in Orlando, Florida, February 15-16.

The Biosimilars Forum's Julie Reed Shares Her Major Goals for the Organization in New Role

February 13th 2022

By Skylar Jeremias

Video

Improving access and getting big legislative changes for biosimilars passed are just some of the many plans that Julie M. Reed, the new executive director of the Biosimilars Forum, has for the organization.

What's Holding Up Biosimilar Uptake? Misconceptions, Misaligned Incentives, Panelists Say

January 26th 2022

By Skylar Jeremias

Article

US biosimilar uptake faces several barriers, including misconceptions regarding biosimilar efficacy and a misalignment of prescription incentives between payers, providers, and patients, panelists discussed.